Beranda › Kanker Paru Non-Sel Kecil › Montana › Billings
Uji klinis Kanker Paru Non-Sel Kecil di Billings, MT
17 studi untuk Kanker Paru Non-Sel Kecil mencari peserta di lokasi sekitar Billings (dalam radius sekitar 30 mil). Buka studi untuk melihat kriteria peserta dan cara menghubungi tim studi.
Teks studi resmi (Bahasa Inggris)
Merekrut peserta untuk studi di sini? Tampilkan di bagian atas halaman ini — $99 selama 30 hari →
A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)
Menerima pesertaFase 3
- St. Vincent Frontier Cancer Center-Research ( Site 0105), Billings
Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial
Menerima pesertaFase 3
- Billings Clinic Cancer Center, Billings
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
Menerima pesertaFase 3
- Billings Clinic Cancer Center, Billings
A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)
Menerima pesertaFase 3
- Billings Clinic ( Site 3255), Billings
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
Menerima pesertaFase 3
- Billings Clinic Cancer Center, Billings
- Saint Vincent Frontier Cancer Center, Billings
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
Menerima pesertaFase 3
- St. Vincent Frontier Cancer Center, Billings
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
Menerima pesertaFase 3
- Intermountain Health St. Vincent Regional Hospital - Cancer Centers of Montana, Billings
This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
Menerima pesertaFase 3
- SCL Health - Montana, Billings
- SCL Health - Montana, Billings
Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
Menerima pesertaFase 2
- Billings Clinic Cancer Center, Billings
Study to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung Cancer
Menerima pesertaFase 2
- St. Vincent Frontier Cancer Center, Billings
Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
Menerima pesertaFase 1/2
- Intermountain Health - St. Vincent Frontier Cancer Center, Billings
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
Menerima pesertaFase 2
- Billings Clinic Cancer Center, Billings
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)
Menerima pesertaFase 2
- Billings Clinic Cancer Center, Billings
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
Menerima pesertaFase 2/3
- Billings Clinic Cancer Center, Billings
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
Menerima pesertaFase 2
- Billings Clinic Cancer Center, Billings
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
Menerima pesertaStudi observasional
- Billings Clinic Cancer Center, Billings
- Montana Cancer Consortium NCORP, Billings
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Menerima pesertaStudi observasional
- Massive Bio SYNERGY-AI site, Billings
Uji klinis Kanker Paru Non-Sel Kecil di kota lain
- Houston, TX145 studi
- New York City, NY121 studi
- Arlington, VA104 studi
- Nashville, TN97 studi
- Boston, MA90 studi
- Los Angeles, CA87 studi
- St. Louis, MO73 studi
- Chicago, IL61 studi
- Baltimore, MD60 studi
- San Antonio, TX59 studi
- Columbus, OH57 studi
- Washington, DC55 studi
Studi lain di Billings
- Kanker Prostat15 studi
- Kanker Paru13 studi
- Kanker Payudara10 studi
- Kanker Ovarium9 studi
- Melanoma7 studi
- Leukemia Limfositik Kronis7 studi
- Leukemia Mieloid Akut7 studi
- Kanker Kandung Kemih6 studi
- Kanker Kolon6 studi
- Kanker Kolorektal6 studi
- Kanker Rektum5 studi
- Karsinoma Sel Skuamosa Kepala dan Leher4 studi
Dari ClinicalTrials.gov, data diambil 6 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.